Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cephalon and ImmuPharma enter option agreement

Cephalon and ImmuPharma enter option agreement

26th November 2008

Cephalon and British-based ImmuPharma have signed an option agreement.

The deal will see an exclusive and worldwide licence for the experimental Lupus drug, Lupuzor and will see Cephalon paying $15 million (9.77 million pounds) to its partner.

If the current phase IIb trials prove to be a success, ImmuPharma has also said it would receive a one-time fee, royalties and milestone payments.

Dimitri Dimitriou, chief executive officer at ImmuPharma, said: “We are truly delighted to have this agreement with Cephalon and believe they would be a great partner to take Lupuzor forward.”

“It represents an important landmark for the company and secures the future for our most advanced asset.”

Lupuzor is described by the company as a first-in-class immune modulating treatment which has been shown to play a critical role in the physiopathology of Lupus.

Composition of matter patents for Lupuzor has been approved in Japan and Australia, with the US Patent Office recently issuing a notice of allowance.

In other news, a drug by Cepahlon that is used to treat patients with Relapsed Indolent non-Hodgkin’s Lymphoma (NHL), has received approval by the US Food and Drug Administration (FDA).

The endorsement of Treanda (bendamustine hydrochloride) means it will be a treatment of patients with chronic lymphocytic leukemia, the most common form of the cancer in the US.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.